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Letters to the Editor 
Dear Editor 
Pneumothorax resulting from bronchial brushing during 
fibre-optic bronchoscopy 
Fibre-optic bronchoscopy (FOB) is a generally 
well tolerated procedure with a low incidence of com- 
plications. Bronchial brushings to obtain cytological 
specimens during FOB is a useful test in the diagnosis 
of bronchial carcinoma, either as an adjunct to 
bronchial or transbronchial biopsy, or in cases where 
biopsy is not safe or not possible. It is regarded as a safe 
procedure adding little extra risk to the bronchoscopy. 
Pneumothorax, when it occurs during FOB, tends to 
be related to transbronchial biopsy, although it has 
been reported following bronchoalveolar lavage (1). 
We report the case of a man who developed a 
pneumothorax during FOB as a result of bronchial 
brushings being performed. 
A 50-year-old male smoker was referred to the Chest 
Clinic with haemoptysis and recurrent cough. Chest 
radiograph showed a left hilum suspicious of an under- 
lying central bronchial neoplasm and he was therefore 
referred for FOB. No endobronchial lesion was seen, 
therefore a cytology brush was passed into the anterior 
and apicoposterior segments of the left upper lobe to 
obtain specimens. During the procedure he com- 
plained of left-sided chest pain. Clinical examination 
showed him to have reduced breath sounds on the left 
side and a subsequent chest radiograph demonstrated 
a 40% left-sided pneumothorax. The lung re- 
expanded satisfactorily following intercostal needle 
aspiration and he was discharged home the following 
day. Cytology from the brushings was benign and the 
radiological hilar abnormality proved to be a vascular 
shadow following a computerized axial tomography 
scan. 
Most chest physicians only perform chest radio- 
graphs following FOB if a transbronchial biopsy has 
been taken. Studies have suggested that routinely 
performing a chest radiograph following FOB is un- 
necessary if a pneumothorax is not clinically suspected 
and that this merely adds to the cost of the procedure 
(2,3). However, the clinical signs of pneumothorax 
are notoriously unreliable and, although chest pain is 
not an uncommon complaint following FOB, the 
consequences of missing a pneumothorax are poten- 
tially serious if tension ensues. Pneumothorax may 
therefore complicate FOB even if biopsies have not 
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been taken and, although we do not advocate a routine 
chest radiograph in all patients following FOB, we 
would suggest that a chest radiograph be obtained in 
those patients who complain of chest pain during or 
after this procedure. 
R.P. SMITH AND B.J. LIPWORTH 
Department of Respiratory Medicine, 
King’s Cross Hospital, 
Dundee, U.K. 
5 July 1991 
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Dear Editor 
Early management of community-acquired asthma 
We read with interest the paper by Drs Tang and 
Macfarlane (1) concerning fatal cases of community- 
acquired pneumonia (CAP). Like several previous 
audits of pneumonia, their study found that there was 
a delay of greater than 4 h prior to the administration 
of antibiotics to patients with severe pneumonia. 
Our experience in Salford is similar (2). We have 
reported a mean delay of 6.9 h from arrival in hospital 
to first antibiotic treatment in unselected cases of 
community-acquired pneumonia (12 h for oral treat- 
ment; 3.2 h for i.v. treatment). After this audit, we 
instituted hospital-wide guidelines for the manage- 
ment of CAP. These guidelines specified that the first 
dose of antibiotic should be given intravenously by the 
admitting doctor. Re-audit 1 year later showed a 62% 
reduction (to 2.6 h) in ‘door to treatment’ time. In 
the 22 cases where i.v. treatment was given, the mean 
time to treatment was only 2.2 h. This may be the best 
achievable average figure in view of the need for 
medical assessment and chest radiograph prior to 
treatment in most cases. 
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